At this year’s European Society for Medical Oncology (ESMO) Annual Meeting, pharmaphorum web editor Nicole Raleigh spoke with ...

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...

Interestingly, while only 16% of oncology researchers reported using AI in biomarker detection and assessment at the time of ...

The results – presented at the ESMO cancer congress and simultaneously published in Annals of Oncology – come after seven ...

Millions of women worldwide live with endometriosis, which causes symptoms like pain and extreme tiredness and, if untreated, ...

On Friday 17th October, the European Society for Medical Oncology’s Annual Meeting 2025 kicked off, with the opening press ...

Researchers in the UK have started recruiting patients for a large-scale trial that will test a battery of Parkinson's ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...

Activist investor Shah Capital has called on the board of directors at Novavax to put the company up for sale, citing a ...

Debruyne has said that in recent years Bavarian Nordic has received several enquiries about a takeover but has never actively ...

Reimbursement authority NICE has said that Apretude (cabotegravir) can now be used as an alternative to daily oral PrEP pills ...

Merck KGaA has become the third pharma company to reach an agreement with the Trump administration to cut the cost of some of its medicines in return for a reprieve from US tariffs on pharma imports.